# Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

> **NCT00080106** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 114 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** MRK Ad5 HIV-1 gag vaccine
- **OTHER:** Vaccine placebo

## Key facts

- **NCT ID:** NCT00080106
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2007-09
- **Final completion:** 2011-05
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080106, "Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00080106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*